SecBot SecBot
8-K ·Filed Aug 6, 2026

TARS

Tarsus Pharmaceuticals, Inc.
MIXED
Impact 6/10
Horizonweeks Processed3mo ago SEC0001819790-26-000063
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The strong revenue beat and guidance raise support the bull case for XDEMVY's commercial trajectory, but the massive EPS miss and $125M dilutive PIPE create near-term overhang. Watch for details on the Alkeus acquisition terms and integration costs, and monitor Q3 prescription trends to confirm demand momentum.

DirectionMixed
Confidencehigh
Horizonweeks

ALK-001

● Neutral Named in this 8-K
Impact
Phase
Phase 3
Time to market
If the Phase 3 NORTHSTAR trial succeeds, potential FDA approval would likely follow in 2030 or later, given topline data is not expected until H2 2029.
Next catalyst
None dated

What to watchALK-001 has no near-term binary catalyst, the Phase 3 NORTHSTAR topline readout is not expected until H2 2029. TARS stock will be driven primarily by XDEMVY commercial execution and nearer-term pipeline catalysts (TP-04, TP-05) over the next 12 months. Monitor the Alkeus acquisition close and any early NORTHSTAR enrollment updates, but do not trade TARS on ALK-001 expectations alone.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$65.33
T+0 close · Aug 6, 2026 · via day close
Latest settled
+14.57%
T+60 · $74.85
Vs SPY
+16.24%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $65.33entry
  2. T+1 · 3mo ago −0.83%α −1.44% · $64.79
  3. T+5 · 3mo ago +5.43%α +4.22% · $68.88
  4. T+20 · 3mo ago +27.36%α +26.76% · $83.21
  5. T+60 · 18d ago +14.57%α +16.24% · $74.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tarsus reported Q2 2026 product sales of $173.9M (+69% YoY) and raised full-year XDEMVY guidance to $685-705M, but EPS of -$0.43 missed consensus of -$0.20 by 119%. The company also announced a pending acquisition of Alkeus Pharmaceuticals and a $125M private placement, expanding into retina with a Phase 3 Stargardt disease program. The strong revenue beat and guidance raise are offset by the massive EPS miss and dilution from the financing, creating a mixed picture for traders.

Key Financial Metrics

EPS
−$0.43
est −$0.20 · -119.4%
Revenue
$173.9M
est $169.5M · +2.6% · +69.4% YoY
Rating
miss
Guidance
$685M-$705M
raised
Gross Margin
93%

Key Facts

  • Q2 2026 XDEMVY net product sales of $173.9M, up >69% YoY from $102.7M
  • Full-year 2026 XDEMVY guidance raised to $685-705M from prior $670-700M
  • GAAP EPS of -$0.43 missed consensus of -$0.20 (-119.4% surprise)
  • Net loss of $18.6M vs $20.3M in prior year; operating loss widened to $19.9M
  • Cash, equivalents and marketable securities at $449.7M as of June 30, 2026
  • Announced pending acquisition of Alkeus Pharmaceuticals (ALK-001 for Stargardt disease)
  • Priced $125M private placement financing with top-tier funds
  • Completed acquisition of iRenix Medical (IRX-101 ocular antiseptic)
  • SG&A expenses surged to $150.7M (+46% YoY) on DTC and commercial expansion
  • R&D expenses nearly doubled to $31.0M (+99% YoY) driven by TP-05 Calliope trial

Financial Impact

Q2 product sales $173.9M (+69% YoY); EPS -$0.43 vs consensus -$0.20; guidance raised to $685-705M; $125M PIPE financing

revenueepsdilutioncash

Risk Factors

  • Massive EPS miss (-119%) signals operating leverage is deteriorating faster than expected
  • $125M PIPE financing dilutes existing shareholders and adds execution risk for the Alkeus acquisition
  • SG&A spending growth (+46% YoY) may not sustain if revenue growth decelerates
  • Pipeline catalysts (TP-04, TP-05, IRX-101) are years away from commercialization

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001819790-26-000063
Document: tars-20260806.htm0001819790-26-000063
Document: 0001819790-26-000063-index-headers.html0001819790-26-000063
Document: 0001819790-26-000063-index.html0001819790-26-000063
Document: 0001819790-26-000063.txt0001819790-26-000063
8-K Data (Synthetic)0001819790-26-000063

Track record

21 reports on TARS

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 6, 2026